Want to see HK:9886 full AI Analyst Report?
9886 Stock Chart & Stats
HK$0.81
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$0.81
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.54 - HK$1.37
Previous CloseN/A
Volume21.50K
Average Volume (3M)4.91M
Market Cap
HK$915.16M
Enterprise ValueHK$845.29M
Total Cash (Recent Filing)HK$1.12B
Total Debt (Recent Filing)HK$281.81M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,240,312,900
10 Day Avg. Volume8,114,443
30 Day Avg. Volume4,906,414
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.35
Revenue Forecast (FY)HK$126.42B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA 70.2% revenue rebound in 2025 reflects a meaningful recovery in demand and execution. Sustained top-line growth increases scale, improves fixed-cost absorption, and creates room to reinvest in pharmacy retail and fulfillment capabilities, supporting a durable path toward profitability if maintained over multiple quarters.
Margin ImprovementExpansion of gross margin to ~35.3% alongside a sharp narrowing of losses (net margin ~-1.0%) indicates improving unit economics and cost control. If margin gains are driven by sustainable mix or efficiency changes rather than one-off items, this supports converting revenue growth into lasting operating profitability.
Cash Generation And Manageable LeverageA swing to positive operating (~155M) and free cash flow (~123M) combined with debt-to-equity roughly 0.06–0.18 materially enhances financial flexibility. Stronger cash generation and low leverage support investment in distribution, reduce refinancing risk, and improve the company's ability to withstand economic cycles.
Bears Say
Still Slightly UnprofitableDespite improvement, the company remained slightly unprofitable and reported negative ROE across 2022–2025. Persistently negative returns limit retained earnings growth and constrain internal funding for expansion, meaning the recovery must continue into multiple periods to cement durable capital generation and shareholder value.
Historical Balance-sheet StressA past episode of negative equity and very high leverage in 2020–2021 highlights prior execution failures and funding stress. That history increases the risk that future operational setbacks or market disruption could quickly strain liquidity or access to capital, making balance-sheet resilience a continuing structural concern.
Cash-flow VolatilityCash generation improved in 2025 but follows multi-year negative cash flows, and management notes timing or working-capital factors. Volatile cash conversion complicates planning, limits reliable reinvestment or debt paydown, and means the company needs multi-year consistent free cash flow to prove the turnaround is durable.
Dingdang Health Technology Group Ltd. News
9886 FAQ
What was Dingdang Health Technology Group Ltd.’s price range in the past 12 months?
Dingdang Health Technology Group Ltd. lowest stock price was HK$0.54 and its highest was HK$1.37 in the past 12 months.
What is Dingdang Health Technology Group Ltd.’s market cap?
Dingdang Health Technology Group Ltd.’s market cap is HK$915.16M.
When is Dingdang Health Technology Group Ltd.’s upcoming earnings report date?
Dingdang Health Technology Group Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 16 days.
How were Dingdang Health Technology Group Ltd.’s earnings last quarter?
Dingdang Health Technology Group Ltd. released its earnings results on Mar 20, 2026. The company reported HK$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.002.
Is Dingdang Health Technology Group Ltd. overvalued?
According to Wall Street analysts Dingdang Health Technology Group Ltd.’s price is currently Overvalued.
Does Dingdang Health Technology Group Ltd. pay dividends?
Dingdang Health Technology Group Ltd. does not currently pay dividends.
What is Dingdang Health Technology Group Ltd.’s EPS estimate?
Dingdang Health Technology Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dingdang Health Technology Group Ltd. have?
Dingdang Health Technology Group Ltd. has 1,240,312,900 shares outstanding.
What happened to Dingdang Health Technology Group Ltd.’s price movement after its last earnings report?
Dingdang Health Technology Group Ltd. reported an EPS of HK$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.205%.
Which hedge fund is a major shareholder of Dingdang Health Technology Group Ltd.?
Currently, no hedge funds are holding shares in HK:9886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dingdang Health Technology Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.67%
Trailing 12-Months
Company Description
Dingdang Health Technology Group Ltd.
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is based in Beijing, China.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
EC Healthcare
―
Giant Biogene Holding Co. Ltd.
―